Last reviewed · How we verify

NTQ1062+Fulvestrant — Competitive Intelligence Brief

NTQ1062+Fulvestrant (NTQ1062+Fulvestrant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor degrader / Estrogen receptor antagonist combination. Area: Oncology.

phase 3 Estrogen receptor degrader / Estrogen receptor antagonist combination Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NTQ1062+Fulvestrant (NTQ1062+Fulvestrant) — Nanjing Chia-tai Tianqing Pharmaceutical. NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NTQ1062+Fulvestrant TARGET NTQ1062+Fulvestrant Nanjing Chia-tai Tianqing Pharmaceutical phase 3 Estrogen receptor degrader / Estrogen receptor antagonist combination Estrogen receptor alpha (ERα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor degrader / Estrogen receptor antagonist combination class)

  1. Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NTQ1062+Fulvestrant — Competitive Intelligence Brief. https://druglandscape.com/ci/ntq1062-fulvestrant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: